Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This study will evaluate the efficacy, safety and effect on quality of life of weekly paclitaxel plus bevacizumab as first line treatment in elderly patients (≥ 70 years old) with metastatic breast cancer. Furthermore, the efficacy of the combination therapy will be correlated with the functional status of patients according to the comprehensive geriatric assessment.
Critère d'inclusion
- Breast Cancer